ISIS Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 9.35B 8.21B 7.63B 7B 13.16B 900B 13.36B 90.65B 35.41B 442B 35.08B 34.33B 1,530B | P/E 2026 * |
-15.7x | P/E 2027 * | -31.9x |
|---|---|---|---|---|---|
| Enterprise Value | 9.09B 7.99B 7.43B 6.82B 12.81B 876B 13B 88.2B 34.46B 431B 34.14B 33.4B 1,489B | EV / Sales 2026 * |
10.2x | EV / Sales 2027 * | 6.64x |
| Free-Float |
99.08% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Director/Board Member | 73 | 01/05/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 25/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 9.35B | |
| +1.15% | -2.44% | -2.48% | +9.93% | 46.86B | |
| +0.25% | +1.65% | +399.22% | +647.65% | 40.23B | |
| -0.27% | +4.45% | +11.81% | +60.81% | 36.23B | |
| +0.35% | +0.87% | +4.46% | -10.31% | 34.72B | |
| +3.14% | +1.02% | +4.76% | +43.00% | 27.89B | |
| -0.73% | +11.84% | +34.39% | +134.44% | 16.79B | |
| +0.47% | -2.74% | - | - | 16.74B | |
| +1.27% | -5.43% | +2.78% | +8.28% | 13.12B | |
| -2.68% | -2.49% | -11.36% | -34.51% | 12.7B | |
| Average | +0.43% | +0.83% | +55.45% | +107.41% | 27.25B | |
| Weighted average by Cap. | +0.57% | +0.91% | +74.95% | +137.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 890M 782M 727M 667M 1.25B 85.73B 1.27B 8.63B 3.37B 42.15B 3.34B 3.27B 146B | 1.39B 1.22B 1.14B 1.04B 1.96B 134B 1.99B 13.51B 5.28B 65.94B 5.23B 5.12B 228B |
| Net income | -596M -524M -487M -447M -840M -57.41B -852M -5.78B -2.26B -28.22B -2.24B -2.19B -97.58B | -283M -249M -231M -212M -399M -27.26B -405M -2.75B -1.07B -13.4B -1.06B -1.04B -46.34B |
| Net Debt | -252M -221M -206M -189M -355M -24.27B -360M -2.44B -955M -11.93B -946M -926M -41.26B | -101M -88.7M -82.49M -75.7M -142M -9.73B -144M -980M -383M -4.78B -379M -371M -16.53B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
